Genetherapy

Story Summary: Women are more likely than men to get the disease and it is the most common neurologically disabling disease in young adults. In the U. S. , upwards of 95% of adults are infected with the virus, but free of symptoms. This is the first study based on the longitudinal follow-up of several thousand individuals who were not infected with EBV at the time of recruitment. The study population was made up of active-duty US Army, Navy, and Marines personnel who have at least one blood sample in the Department of Defense Serum Repository. The researchers selected 305 individuals diagnosed with MS and who had blood specimens collected before the date of their diagnosis. The study found that MS risk is extremely low among individuals not infected with EBV, but it increases sharply in the same individuals following EBV infection. The observation that MS occurred only after EBV is a big step forward, said Alberto Ascherio….Read the Full Story

Related posts:

1. Epstein-Barr Virus Linked to MS
2. Drugs May Shut Down Several Epstein-Barr Virus-Induced Diseases
3. Key Mechanism For The Proliferation Of Epstein Barr Virus Discovered

Story Summary: Ms. Jones comes to VGXI from Beckman-Coulter, Inc. where she was the Quality Assurance Engineering Supervisor and Calibration Manager. Mr. Colvin joins VGXI from Merck & Co. , where he was responsible for selling cardiovascular and diabetic medications to cardiologists, endocrinologists and primary care physicians. Prior to joining Merck in 2006, he was the co-founder of SYNTHEGEN, LLC, a biotechnology company that marketed reagents for genomics research. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. Cautionary Factors That May Affect Future Results- Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise….Read the Full Story

Related posts:

1. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
2. Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics
3. TapImmune Announces Acquisition of Additional Technology

Story Summary: Increasingly, people are becoming infected with strains that are resistant to every antibiotic. They then collaborated with University of Washington human geneticists Jay Vary, Thomas Hawn and Mary-Claire King and others in Vietnam and Nepal to validate their findings in human populations. A second study in the same issue of Cell approached the question in another way. Kanury Rao and his colleagues at the International Centre for Genetic Engineering and Biotechnology in India used a genome-wide analysis to produce what now becomes a resource for TB researchers everywhere. Interestingly, they showed that the shape of that interaction varies depending on which isolated strain of TB one considers, suggesting that the different strains rely on somewhat different tactics for successful infection. We identify a core set of molecules which can be targeted through drug development efforts to treat both drug sensitive and multiple drug resistant forms of TB infection. The discovery of LTA4H as a TB susceptibility gene may have clinical implications too, even if it doesnt offer a direct path to a better vaccine, Ramakrishnan says. For one thing, the finding that medium activity of the immune enzyme is best when it comes to TB might help to explain something that has been known but not well understood in clinical circles: people with hard-to-treat TB sometimes improve when they are given anti-inflammatory, immunosuppressive therapies along with more standard drug treatments alone….Read the Full Story

Related posts:

1. Genetic variant offers protection against TB and leprosy
2. Researchers discover gene that affects susceptibility to tuberculosis and clues to how it works
3. Two Research Teams Funded Through the Innovative Partnership Program Between Canada and California to Advance Cancer Stem Cell Research

Story Summary: In this recent experiment, after an ischemic stroke, neurological function in the rat models was significantly improved, apparently by remyelination of neuronal axons induced by Tb4. The research was presented by Dr. Morris, representing the Departments of Neurology and Emergency Medicine, Henry Ford Health System, Detroit, MI, at the International Stroke Conference, San Antonio, TX, February 23-26, 2010. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System. It is currently in Phase 2 clinical development for dermal and ophthalmic wound healing and has now completed a Phase 1 clinical trial supporting delivery of RGN-352 for acute cardiovascular and other indications requiring systemic administration. It is currently in Phase 2 clinical development for dermal and ophthalmic wound healing and has now completed a Phase 1 clinical trial supporting delivery of RGN-352 for acute cardiovascular and other indications requiring systemic administration. Tb4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class, multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, and collagen deposition, while down-regulating inflammation. Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Further, the research described herein regarding Tb4s effect in stoke models may not prove to be beneficial or may not result in any commercial or profitable products. Any forward-looking statements in this press release represent the Companys views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date….Read the Full Story

Related posts:

1. Researchers Report Novel Biological Properties of Fragments of Thymosin Beta 4
2. Researchers Report Elevated Levels of TI24 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
3. Scientists Report Impressive Research Results with TI24 on First Day of Thymosin Meeting

Large-scale UK study finds that just a single cup of coffee a day cuts stroke risk by 30%.

More…

University of California researchers project that the nation’s oldest men and women will experience an 18% annual dementia incidence that increases with age.

More…

Vitamin B3, niacin, is shown to assist with the recovery of brain function, in a lab animal model of stroke.

More…

Story Summary: Its another test being peddled without enough research to show it really works, they say. Gene testing originally was aimed at finding risk for things like cancer, diabetes and Alzheimers disease. Lately, genes have been linked to things you might not suspect, such as stuttering or compulsive leg-jiggling. The company, Waltham, Mass. -based Interleukin Genetics Inc. , looked at studies on hundreds of genes and chose three genes that show a pattern for metabolizing fats and carbohydrates, said its chief scientific officer, Ken Korman. The company then hired Stanford researchers to do a validation study of its $149 test, using people who took part in diet research that was published in 2007. About one-third of the original participants, 138 women, sent cheek swabs with their DNA to Interleukin, which tagged them as low-carb appropriate or low-fat appropriate. Sticking with a diet is more important than what diet you choose, as is not regaining weight, Eckel said. I now know why I gained it back, she said – the gene test showed she does not metabolize carbohydrates well. More recently, she has been on a high-protein diet and weighs 180. When I eat a lot of carbohydrates, I tend to put on weight….Read the Full Story

Related posts:

1. Eating a low energy density diet can offset influence of obesity gene
2. Mice Can Eat Junk And Not Get Fat: Researchers Find Gene That Protects High-fat-diet Mice From Obesity
3. Discovery Of Gene That Protects High-Fat-Diet Mice From Obesity

Aesthetic Trends & Technologies
March | April 2010
Wellness Department

By Paula Simpson, B.A.Sc. (Nutrition), R.N.C.P., Contributing Editor & Advisor

The aging process is one of the best examples of the effects of deteriorating homeostasis. Aging is accompanied by an impairment of the physiological systems including the homeostatic systems such as the immune system. The free radical theory of aging (one of the most widely accepted theories) proposes to explain aging according to which oxygen-derived free radicals cause age-related impairment through oxidative damage to biomolecules, with mitochondria being the main target of free radical attack. Since oxygen radicals are needed for many metabolic and physiological processes, a balance between radical production and their antioxidant-linked inactivation is required to preserve health.

The skin, being the largest organ in the body and barrier from the external environment, is very susceptible to damage produced by free radicals due to its constant contact with oxygen and other environmental stressors, such as UV exposure. This damage caused by free radicals impairs the ability of the cells to transport nutrients, eliminate wastes, and reproduce healthy skin cells, in turn causing an
accumulation of chemical events and by products that deteriorate and interfere with the normal functions of the skin. Over time, inflammation and the degradation of collagen and elastin reveal the signs of physical aging of the skin.

Chronic sun exposure, smoking, poor dietary intake, and lifestyle have been well documented as key accelerators in skin aging due to an imbalanced homeostasis. Clinical studies show that age-dependent changes of the immune system are linked to oxidative stress and that an adequate intake of dietary antioxidants may protect those systems (including skin) against…READ ON – Click Here to Download Article

About Ms. Simpson
Paula Simpson, B.A.Sc. (Nutrition), R.N.C.P. is the Executive Director of Isocell North America and holds a degree in Nutrition. She has over 15 years of experience in consulting, public relations, product formulation, and program development for the Nutraceutical and Medical Aesthetic Industry. Her role as a Scientific Evaluator and Regulatory Consultant for some of the top nutraceutical companies worldwide has solidified her reputation as a leader in research and development for innovative natural health products. As a Project Leader, Paula developed and guided an international weight loss program towards a successful launch in North America and Europe. As the Nutrition Director for a medical spa, she developed a weight management and longevity program that was the impetus for the company’s overall commercial success. Ms. Simpson can be contacted directly at paula.simpson@glisodinskin.com. Visit their website on the worldwide web: www.glisodinskin.com.

Aesthetic Trends & Technologies
March | April 2010 Issue
Practice Management Department

By Wendy Lewis, Contributing Editor & Advisor

If you wonder why some medical practices and certain doctors seem to receive all the media coverage, the reason is that they have someone behind the scenes making it happen. Ultimately, the goal of a public relations campaign is to generate exposure for your practice or medspa and your brand by employing a variety of media vehicles to reach your targeted consumer. A well orchestrated public relations program allows you to create long-term relationships with key media that may include editors, writers, producers, researchers, reporters, anchors, presenters, bloggers, and their assistants, associates, and colleagues.

Placements generated may include television segments, radio programs, local newspapers, national publications, monthly magazines, newsletters, websites, ezines, and blogs. PR is a key component of your brand strategy because it is a vehicle that can be driven but not fully controlled by you. Thus, a third-party endorsement reinforces and authenticates the message of your expertise to prospective patients and customers in a way…READ ON – Click Here to Download Article

About Ms. Lewis
Wendy Lewis is the President of Wendy Lewis & Co., Ltd., global aesthetics consultancy established in 1997 and an internationally renowned expert in social media strategy and practice marketing. She is the author of 10 books on aesthetics and beauty and Founder and Editor in Chief of www.beautyinthebag.com. Contact her at 1.877.WLBEAUTY; wl@wlbeauty.com. Visit her on the worldwide web: www.cosmeticmedrx.com.

Aesthetic Trends & Technologies
March | April 2010
Plastic Surgery Department

By Joseph A. Eviatar, M.D., F.A.C.S.

The U.S. Food and Drug Administration (FDA) has recently approved Dysport™, a “next generation” acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement of the appearance of moderate to severe glabellar or frown lines between the brows. Dysport, marketed by Medicis Aesthetics, the distributers of Restylane and Perlane, has been used in over two million treatments worldwide in 27 countries.

STAYING POWER OF DYSPORT
In the seven years since its FDA clearance, BOTOX® Cosmetic has taken the aesthetic world by storm. Yet, the chief complaint among BOTOX® patients is its staying power. Many come to experience injection fatigue where the duration between treatments becomes shorter and shorter. This is where Dysport may outshine BOTOX®.

Clinical studies and patient reports have shown that Dysport may last up to six months compared to the four to five months that BOTOX® is effective. Research also shows Dysport takes effect more quickly, usually within 48 hours. In addition to frown lines, Dysport is used (off label) around the eyes (crow’s feet), for brow lifting, and on the forehead to reduce dynamic lines and wrinkles. It can also be used to treat prominent neck bands or cords. Although great results are…READ ON – Click Here to Download Article

About Dr. Eviatar
Joseph A. Eviatar, M.D., F.A.C.S., is an Assistant Clinical Professor of Ophthalmology at New York Medical College, an Attending Surgeon at New York Eye & Ear Infirmary and Director of Oculoplastics at SUNY School of Optometry. He performs medical research, lectures to his colleagues, and is often featured in the press. He is a recognized expert in multiple cosmetic non-invasive treatments and has performed thousands of surgical and laser procedures for aesthetic facial rejuvenation and reconstruction. For more information on this topic, please contact Dr. Eviatar at: 212.272.3717or visit his website at: www.chelseaeye.com.

Aesthetic Trends & Technologies
March | April 2010
Plastic Surgery Department

By Todd K. Malan, M.D.

Recent technological advances have allowed me to pioneer a procedure, the Stem Cell Enhanced Natural Breast Augmentation, which incorporates the latest advances in fat harvesting, adult stem cell transfers, and breast splinting technology to provide women the option of enlarging their breasts using their own fat, eliminating the need of unnatural implants.

HISTORICAL DATA
Since the late 1980s, autologous fat transfer for breast augmentation and reconstruction has remained a highly controversial procedure following its introduction in the U.S. Concerns regarding poor graft, survival, calcifications, liponecrotic cysts, and obscuring mammography had relegated this procedure to little more than a historical footnote. Modern advances in fat harvesting and transfer techniques, digital mammography, and the use of adipose derived adult stem cells and regenerative cells demand a reexamination of this long-standing bias against fat transfer breast augmentation.

Free fat for body contour correction has been widely accepted and is considered an excellent technique throughout the cosmetic industry. Since fat has a higher viscosity than normal saline and shares a similar texture and feel as normal breast tissue, it seems logical to replace…READ ON – Click Here to Download Article

About Dr. Malan
Todd K. Malan, M.D.. founded the Innovative Cosmetic Surgery Center in Scottsdale AZ to help improve advanced research and physician training in minimally invasive cosmetic surgery techniques and to provide patients with safe and reliable options to traditional surgery.

Dr. Malan continuously expands his knowledge and training to maintain industry leadership, which constantly places him at the forefront of advancements. He is a nationally recognized speaker and educator on the Natural Breast Augmentation and advanced body contouring procedures. His expertise is evident through his respected surgery center, technological developments, loyal patient following, and peer recognition. For more information about this topic, please visit Dr. Malan on the worldwide web: www.smartliposurgery.com, or call: 866.985.7999.

Aesthetic Trends & Technologies
March | April 2010
Organics & Green Department

By Emily Stocker, Contributing Editor & Advisor

Think of beauty products the same way you do the food that you put in your body. Top chefs in elegant restaurants use high-quality ingredients, fresh herbs, and real spices. They do not use artificial flavors or synthetic ingredients simply because it would compromise the integrity of their food.

The recent increase in public awareness of the actual ingredients contained within the food we eat has led mindful consumers to become “label readers” in an effort to control what they put into their bodies. The international organic food production has grown at a rate of around 20 percent a year since the early 1990s. Naturally, the trends of organic beauty products have begun to run parallel with those of the organic food industry, growing by 15 percent annually over the past fifteen years. However, such extensive growth of the industry has placed “organic” labeled products under the scrutiny of watchful consumers.

Nowhere does the label “organic” take a more gratuitous bruising than in the beauty products industry. There are clear guidelines for organic food because organic industry standards were designed specifically for food production. When you see the word organic on a beauty product, it may not mean exactly what you presume it to mean. Minimal regulation has allowed for grossly inadequate labeling.

European-based organizations have begun attempts at creating an international industry standard, requiring high levels of organic ingredients – anywhere from 85-95 percent. Although these standards give consumers the impression that little or no chemical ingredients are in the product, they have received harsh criticism from the Organic Consumers Association for…READ ON – Click Here to Download Article

About Ms. Stocker
Emily Stocker steps into the business of being green (and happy) with Em’s Organics, offering products like sea sponge soap made from USDA Organic ingredients and baby and children’s clothing and accessories. And that’s just the beginning. Why buy
organic products? Because they’re better. Visit her website: www.EmsOrganics.com, which will officially launch on April 22nd, Earth Day.

Aesthetic Trends & Technologies
March | April 2010 Issue
Laser & Light Technology Department

By Jeffrey C. Caruth, M.D.

Body contouring to eliminate love handles and other “problem” areas on the abdomen, thighs, under the bra line, and on the hips is one of the most popular cosmetic procedures in the U.S. today. As we all know, even with proper diet and exercise many men and women find it nearly impossible to get rid of bulges and unsightly pockets of fat to achieve the body image they desire.

Liposuction, the traditional method of fat removal, has been effective; but there are often unintended side-effects, including potential damage to connective tissues, the risk of fluid build-up, and a rippling or distortion of the tissues, leading to patient dissatisfaction and requests for a second “touch-up” corrective procedure.

More recent advances, such as the ultrasonic liposuction and laser assisted liposuction, represent an improvement in the technology; but these techniques also continue to have certain drawbacks and inherent risks, including damage to the skin from burns. Now an alternative body contouring innovation has been introduced that takes patient safety, comfort, and satisfaction to the next level.

Cleared by the FDA in summer 2008, the Body-Jet Water-Assisted Liposuction (WAL) offers many advantages both for the physician and the patient. From my experience, the technique is not only an easy one to learn, but it achieves superior results with high patient satisfaction. There is a shorter operating time and a faster recovery period. Patients experience less bruising and reduced pain. Usually, only local anesthesia is needed so the patient is awake…READ ON – Click Here to Download Article

About Dr. Caruth
Jeffrey C. Caruth, M.D., is a Board Certified Gynecologist who is at the leading edge of the many advanced cosmetic surgical techniques. He offers patients the latest advances in body contouring, breast augmentation, and facial rejuvenation and is certified in many of these pioneering innovations, including the new Body-Jet Water-Assisted Liposuction, Fractional CO2 Skin Resurfacing, Advanced BOTOX®, Advanced Filler Injections, Vaser LipoSelection, and SmartLipo Body Contouring. For more information regarding this topic, visit Dr. Caruth’s website: www.planoaesthetics.com.

Aesthetic Trends & Technologies
March | April 2010 Issue
Laser & Light Technology Department

By Jasmina Kozarev, M.D.,
Specialist in Dermatovenerology

The demand for tattoo removal treatments is undeniably growing. Up to 20 million people in the United States have at least one tattoo, and a recent survey suggests that 17% of people sporting a tattoo consider having it removed. The reasons for wanting to remove tattoos are plentiful and so is the multitude of treatments available to patients. Lasers have certainly made their mark in this area in recent years; and there is a plethora of systems out there emphasizing various technical specifications and features, and most importantly carrying different price tags.

Technological developments have not only furthered the treatment of tattoos but have also made the most advanced tattoo removal lasers extremely versatile and applicable in the treatment of various pigmented skin conditions and treatments in Asian skin types. How does laser tattoo removal work? And, as a practitioner looking into expanding your practice’s treatment range, what kind of specifications and features should you look for? We aim to give you some guidance based on concrete practical experience…READ ON – Click Here to Download Article

About Dr. Kozarev
Jasmina Kozarev, M.D., is a graduate of Novi Sad’s Faculty for Medicine and has over 15 years of clinical experience as a specialist in dermatovenerology. She is the founder of the Dr. Kozarev Dermatology Laser Clinic, Serbia, where she practices dermatology and aesthetic laser medicine. She was the first to perform CO2 laser surgery in Serbia and has accumulated a wealth of clinical and academic experience in laser treatments throughout her career.

Given her long-term experience with a tremendous variety of laser sources, Dr. Kozarev is a true expert in the field of Aesthetic Laser Medicine. She contributes to the field both from a practical, clinical point of view, as well as research and development of applications. For more information on the QX MAX, visit the Fotona website: www.fotona.com or call: 888.550.4113.

Aesthetic Trends & Technologies
March | April 2010 Issue
In Practice Department

Practice Philosophy – The Three “A”s

When Dr. Alexander Gross launched his primary dermatology practice almost 20 years ago, he did so with a basic philosophy for success. He adopted a mindset of The Three “A”s: Ability, Affability, and Availability. These core sensibilities are what Dr. Gross believes have set the ground work for sustaining his large and ever-evolving surgical and cosmetic dermatology practice.

• Ability – Having the necessary training and skills to deliver on patient expectations and

• Affability – Making yourself and your team open to establishing a relationship with patients on a personal level – “bedside manner”

• Availability – Being obtainable and reliable as pertains to your patients’ needs for attention and service

ABILITY
When it comes to ability, Dr. Gross practices what he preaches. He received a Bachelor of Science degree from Emory University and then attended medical school at the University of South Florida. He completed an internship and residency in internal medicine at Emory University and a dermatology residency and fellowship at Vanderbilt University. Dr. Gross is board certified in both internal medicine and dermatology.

In addition to his full-time practice at the Georgia Dermatology Center, Dr. Gross is an attending physician at Northside Forsyth Hospital. He volunteers his services to the community, and he also trains other physicians to perform tumescent liposuction and soft tissue filler injections. He is an Assistant Clinical Professor of Dermatology at Emory, a preceptor for…READ ON – Click Here to Download Article

About Dr. Gross
Dr. Gross’s extensive involvement and experience in the field of medicine has led him to many awards and honors. He was named the winner of the Dermatology Abstract Symposium at Vanderbilt University in June of 1990. Because of his dedication and work with The American Cancer Society, Dr. Gross was named Cancer Control Volunteer of the Year in 2008. He recently won the President’s Volunteerism Award, and will serve on the Georgia Composite Medical Board, becoming Chairman July 1st of this year.

Dr. Gross continues to give back to the community with his time and is always available to speak with other medical professionals. To learn more about Dr. Alex Gross and his practice, please visit his website at www.gadermctr.com or contact him directly at axel144@aol.com.

Aesthetic Trends & Technologies
March | April 2010 Issue
Dermatology Department

By Neil S. Sadick, M.D., FAAD, FAACS, FACP, FACPh
Contributing Editor & Advisor

Artefill® was the first nonresorbable soft tissue filler to be cleared by the U.S. Food and Drug Administration. This advanced polymethylmethacrylate (PMMA) microsphere containing dermal filler was cleared by the FDA in October 2006 and is the only permanent filler currently available in the U.S. market today. To date, more than 20,000 patients have been treated with Artefill.

It is well established that PMMA microsphere surface characteristics, purity, and microsphere size are critical factors that influence product safety. Although microsphere quality in PMMA containing products available around the world has improved in recent years, healthcare providers may have misconceptions regarding the safety of newer PMMA fillers, such as Artefill. The previous owners of Artefill along with its current owner and manufacturer (Suneva Medical, San Diego, CA) have invested significant resources to improve the physical/chemical properties, formulation, and processing of Artefill to distinguish it…READ ON – Click Here to Download Article

About Dr. Sadick
Neil Sadick, MD, FAAD, FAACS, FACP, FACPh, is one of the most renowned dermatologists and researchers, and his multiple discoveries have strongly influenced and transformed the future of dermatology. Dr. Sadick’s prestigious list of titles range from Clinical Professor of Dermatology at Weill Cornell Medical College, to President of the Cosmetic Surgery Foundation, Member of the Board of Examiners for the International Society of Hair Restoration Surgery, to Global Medical Advisor for Christian Dior Beauty, to name a few.

He holds four board certifications: Dermatology, Cosmetic Surgery, Internal Medicine, and Hair Transplantation. Dr. Sadick is author, or co-author, of close to 300 articles in peer-reviewed scientific journals and has contributed more than 75 chapters of medical books. In addition, he has written or edited more than 10 books on cosmetic surgery, hair, and vein treatment. Dr. Sadick has also been a guest lecturer at more than 500 medical seminar classes and workshops worldwide. For more information regarding this topic, contact Dr. Sadick at: 212.772.7242 or visit his website: www.sadickdermatology.com.

Aesthetic Trends & Technologies
March | April 2010
Dermatology Department

By Christian Oresajo, Ph.D., Asst. V.P., R&D, L’Oréal USA

Topical application of antioxidants can complement sunscreen to protect the skin from UV damage. Combining natural based antioxidant substances with sunscreen filters can improve protection against UV rays. UV-irradiation is a potent generator of oxidative stress in the skin leading to acute inflammatory reactions, such as erythema, and chronic reactions, such as premature skin aging. Exposure of mammalian skin to UV radiation increases levels of reactive oxygen species, which damages lipids, proteins, and nucleic acids in both epidermis and dermis and contributes to the sunburn reaction as well as photo-aging.

Use of sunscreens for skin photo protection by preventing the penetration of harmful UV rays into skin is well established. However, sunscreens do not provide 100% protection against UV radiation due to various reasons including uneven application, wash-off from body surface, and insufficient protection of UV range. Several recent studies have evaluated the protective role of antioxidants from within the skin…READ ON – CLICK HERE TO DOWNLOAD ARTICLE

About Dr. Oresajo
Christian Oresajo, Ph.D., is currently Assistant Vice President, Research and Development, L’Oréal USA. Prior to joining L’Oréal, Christian worked for over 20 years performing clinical evaluations for top international companies in the personal care industry. He is a member of several professional organizations including the Society of Investigative Dermatology and the American Academy of Dermatology. Christian is coauthor of several publications and book chapters on skin-related topics, including ethnic skin, and is currently an adjunct assistant professor at Howard University School of Medicine, Department of Dermatology, Washington, D.C. He holds a Ph.D. degree in Biochemistry from American University, Washington, D.C. For more information on this topic, visit the La Roche-Posay L’Oréal USA website at: www.anthelios.com, or contact La Roche-Posay directly at: 800.560.1803.

Aesthetic Trends & Technologies
March | April 2010 Issue
Dermatology Department

Preservative-Free Lidocaine Enhanced
Injectable Filler for Added Patient Comfort

By Isaac Starker, M.D.

Juvéderm® XC is a cross-linked hyaluronic acid injectable filler which was cleared for use by the FDA in January 2010. It is distributed by Allergan (Irvine, CA) and has the same FDA cleared indications for use as their Juvéderm Ultra and Ultra Plus products which were introduced in the U.S. in June 2006, namely as an injectable dermal filler at the mid to deep dermis levels for correction of moderate to deep facial wrinkles and folds. An approved example of where it may be injected is the nasolabial folds, the so called parentheses lines. Experienced injectors have also used these products in an off-label fashion in many other facial areas including…READ ON – Click Here to Download Article

About Dr. Starker
Isaac Starker, M.D., F.A.C.S. is a talented Plastic Surgeon whose technical knowledge and artistic eye combine to achieve stunning yet natural appearing plastic surgery results in New Jersey. Dr. Starker performs the full spectrum of cosmetic and reconstructive procedures. He is trained in the latest surgical techniques and in the use of the most advanced technology, including lasers, endoscopy, ultrasound and power-assisted liposuction, and computer imaging.

His surgical philosophy is based upon the premise that successful plastic surgery is a collaboration between patient and surgeon. Dr. Starker feels that he has to take the time to listen to his patient first, and only then can he suggest and perform surgery that will meet his or her wishes. A Fellow of the American College of Surgeons, Dr. Starker earned his undergraduate and medical degrees from New York University and completed general surgery and plastic surgery residencies at St Lukes-Roosevelt, Montefiore and Albert Einstein University Hospitals. He is certified by the American Board of Plastic Surgery and is active in the medical community.

He maintains memberships in numerous professional societies, including American Society for Aesthetic Plastic Surgery, American Society of Plastic Surgeons, New Jersey Society of Plastic Surgeons, and the American Medical Association. For more
information or to contact Dr. Starker, visit the Peer Group website: www.peergroupnj.com.

Aesthetic Trends & Technologies
March | April 2010 Issue
Anti-Aging Department

Porcelain Veneers

Congenitally Missing Teeth Corrected Through an Interdisciplinary Approach

By Brian Kantor, D.D.S., Contributing Editor & Advisor

As technology advances, allowing one’s appearance to be refined, enhanced, and corrected, standards of beauty have reached new levels. This is especially true in the field of cosmetic dentistry, where the once coveted Hollywood smile is now within anyone’s grasp. Simply put, no one wants to be missing front teeth, and today no one has to anymore. While some individuals lose their teeth due to specific circumstances, others are born genetically predisposed to…READ ON – Click Here to Download Article

About Dr. Kantor
Brian Kantor, D.D.S., graduated from the University of Pennsylvania with a BA degree in Biology. He graduated from New York University College of Dentistry and continued his training with an advanced education in General and Cosmetic Dentistry, also at New York University. At the forefront of the cosmetic dentistry revolution, Dr. Kantor has built an enviable reputation for unsurpassed excellence and dedication. He is a partner of the world-renowned dental practice of Lowenberg, Lituchy & Kantor.

He performs state-of-the-art “smile makeovers” using porcelain veneers as well as bonding, bleaching, and porcelain fillings. He has been featured in Gotham Magazine and has appeared on Access Hollywood, the Today Show, and Oprah earlier this year. Dr. Kantor was also featured in W Magazine as “Best Up-and-Coming Beauty Doctors of 2005.” The dental practice of Lowenberg, Lituchy & Kantor has also recently been featured on Regis and Kelly, The View, and innumerable fashion magazines.

Dr. Kantor is an active member in numerous dental societies and organizations, including the Academy of General Dentistry, The American Academy of Cosmetic Dentistry, The International Congress of Oral Implantologists, The American Dental Association, and the Dental Society of the State of New York. To contact Dr. Kantor, call: 212.586.2890, or visit their website: www.lowenbergandlituchy.com.

Story Summary: Study provides breakthrough blueprint for studying differentiation and evolutionNewswise — In a significant leap forward in the understanding of how specific types of tissue are determined to develop in mammals, an international team of scientists has succeeded in mapping the entire network of DNA-binding transcription factors and their interactions. This global network, indicating which factors can combine to determine cell fate, will be published in the March 5 issue of the journal Cell. Transcription factors (TFs) are proteins that bind to specific DNA sequences in order to direct which genes should be turned on or off in a tissue. The integrated approach to systematically map all possible combinations of TFs in mammals has generated large data sets in both humans and mice. The researcher team identified nearly 1,000 different pairs of TF proteins that can be wired together, representing the blueprint of all possible combinations that direct gene expression in mammals….Read the Full Story

Related posts:

1. Transcription factors guide differences in human and chimp brain function
2. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
3. Study reveals why certain drug combinations backfire

Story Summary: aThe BioCartaC/ System has the potential to advance cartilage regeneration and in doing so, change the paradigm in the rehabilitation protocol associated with cartilage injuries. Most recently, the Company entered into a research collaboration with an established West Coast-based company that specializes in orthopaedic repair/regeneration applications. The objective of the development program is to define new solutions to critical orthopaedic issues for patients, such as the development of an injectable ceramic/polymer formulation to carry growth factors for the purpose of bone repair/regeneration applications. About The BioCartaC/Autologous Cartilage SystemThe BioCartaC/Autologous Cartilage System is a minimally invasive, high-quality implant that is currently being investigated for long-term articular cartilage regeneration stemming from joint cartilage defects and injuries. About ProChon Biotech, Ltd. Founded by world leaders in the field of regenerative medicine, ProChon is a privately-held biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration. ProChon owns or possesses patents covering its core technologies and products in the United States, Europe, Israel and Australia, as well as various patent applications that are pending….Read the Full Story

Related posts:

1. ProChon Biotech Closes $3.95 Million Bridge Loan
2. Organogenesis Files PMA for CelTx(TM) for Oral Soft Tissue Regeneration
3. Translational Regenerative Medicine Event Features Venture Forum

Coppertone® Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of the America Academy of Dermatology

Research Reveals Broad Spectrum Sunscreens Containing Antioxidants Can Provide Measurable Skincare Benefits Beyond Sun Protection

WHITEHOUSE STATION, NJ, – Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc., the makers of COPPERTONE®, announced today at the 2010 Annual Meeting of the American Academy of Dermatology the results of studies demonstrating the efficacy of topical antioxidants in broad spectrum sunscreens.

An ex vivo study conducted by an independent researcher for the COPPERTONE® Solar Research Center revealed that using certain antioxidants in sunscreens reduced the formation of damaging free radicals by 74% in skin’s outer layers exposed to UV. This provides significant evidence that sunscreen products containing certain antioxidants can help fortify skin’s natural defenses. The implications of this research are especially pertinent to those whose skin may be more vulnerable to the effects of sun exposure due to outdoor exercise activities.

A separate independent 12-week clinical (in vivo) trial demonstrated that daily use of broad spectrum sunscreens containing specialized blends of antioxidants found in select products in the 2010 COPPERTONE® sunscreen line can provide additional skin health benefits beyond UV protection.

“Emerging research shows that Vitamin E, one of the primary antioxidants in the sunscreen we tested, is a key ingredient for preserving skin’s barrier function and for helping to maintain skin health,” said Robert Bianchini, PhD, Vice President of Research and Development at the COPPERTONE® Solar Research Center. “Since Vitamin E may be lost from the skin during environmental stress, such as outdoor exercise, using a broad spectrum sunscreen with antioxidants proven to help restore these elements is important.”

Not All Antioxidants Are Equal Under UV Light
Ex vivo studies evaluated the overall effectiveness of topical antioxidants contained in the sunscreens for reducing free radical formation caused by sun exposure. Research has shown that not all topical antioxidants are equal under UV conditions. In fact, UV radiation may cause an unexpected reaction with certain topical antioxidants—including some plant extracts—when exposed to sunlight, transforming them into damaging pro-oxidants. For that reason, the researchers tested the antioxidant ingredients used in the sunscreens, COPPERTONE SPORT® with Replenishing Antioxidants and COPPERTONE KIDS® with Protective Vitamins, to ensure they continue to function properly in conditions similar to “real-world” sunscreen use.

The 12-week clinical trial showed that the daily use of sunscreen lotions with the appropriate antioxidants can also provide significant cosmetic benefits. In participants who began the study with signs of mild to moderate photodamage, clinical evaluators saw measurable improvement in a number of parameters that contribute to the cosmetic signs of premature aging, including visible dryness, mottled skin tone, laxity, roughness, and the appearance of fine lines and wrinkles.

“Topical antioxidants are rapidly emerging as a breakthrough innovation in suncare,” added Dr. Bianchini. “The results of our research demonstrate that there are many skin health benefits and applications to adding antioxidants to a sunscreen formula—and we will continue to explore advancements in how this technology can be used with sun protection to help maintain overall skin health.”

About COPPERTONE®
COPPERTONE SPORT® and COPPERTONE KIDS® are registered trademarks of Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc.

About Schering-Plough Consumer HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc.
Today’s Merck is working to help the world be well. Schering-Plough Consumer HealthCare Products, Inc. is the over-the-counter division of Merck. Each day, millions count on one or more of our industry-leading brands that help prevent or treat various common conditions. These include household names such as CLARITIN for allergies, COPPERTONE for sun care, DR. SCHOLL’S for foot care, and many more. Merck. Be well.

Merck / Schering-Plough
908.423.1000
www.merck.com
www.coppertone.com

Story Summary: We look forward to evaluating the Phase 1 data in late 2010 and based on positive outcomes, moving ImmunoVEX into later stage efficacy trials soon thereafter,a said Dr. Robert Coffin, Founder & CTO for BioVex. The causative agent of genital herpes, herpes simplex virus 2, is therefore a very important target for vaccine development, both from a preventive and therapeutic perspective,a said Dr. Simon Barton of the Chelsea and Westminster Hospital, London. Marian Nicholson, Director of the Herpes Viruses Association commented, aWe have been keeping an eye on the progress of ImmunoVEX HSV2for a while and are looking forward to knowing if this vaccine shows promise in the clinic as a protection for people who have not caught the virus and potentially as a therapy for people with frequent outbreaks of herpes simplex type 2. uk, and for more general information on herpes simplex, check the other pages or phone our helpline on +44 845 123 2305. a About ImmunoVEXHSV2ImmunoVEXHSV2is based on a proprietary engineered form of the causative agent of genital herpes, HSV-2, from which genes that collectively interfere with the functions of immune system have been deleted. ImmunoVEXHSV2 expresses all but four of the approximately 80 HSV-2 proteins, maximizing the breadth of the anti-HSV immune response generated, but without the genes encoding for these immune-inhibiting proteins. The vaccine also considerably reduced the level of viral shedding following exposure, which if this translates to the clinical setting, may also reduce any window of infectivity from an infected individual. About Genital HerpesAt least 45 million people over the age of 11 in the United States have been infected with HSV-2, the causative agent of genital herpes, the rate of infection having increased approximately 30% between the late 1970s and the early 1990s, according to the Centers for Disease Control and Prevention. The Companyas lead product, OncoVEXGM-CSFis a first in class oncolytic vaccine. OncoVEXGM-CSFreplicates selectively in tumors; destroying cancer cells whist leaving surrounding healthy cells unharmed. Both local and distant modes of action have been validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have become free of disease. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company recently commenced a Phase 3 study in metastatic melanoma (the OPTiM study) following achieving an unprecedented proportion of durable complete remissions in a Phase 2 study using OncoVEXGM-CSFas a stand alone therapy in patients with advanced disease (see Journal of Clinical Oncology, Vol 27, 2009: pp. In September 2009 the Company received approval from the FDA for a second Phase 3 study, in head and neck cancer, also under the SPA procedure. Chelsea and Westminster has a national, and indeed international reputation, for the excellence of its sexual health and HIV services – it is a centre of not only clinical servicesA but also research. Inquiries about the patient perspective of genital herpes and the background to the stigma associated with the condition should be directed to the HVA – see contact details below. ukA ) Booklets and other materialsA for distribution through sexual health clinics Leaflets and quarterly journals for subscribers,A dealing with all aspects of the virus Talks and study days….Read the Full Story

Related posts:

1. Xcellerex Initiates Phase I Clinical Trial of Novel Yellow Fever Vaccine
2. Hawaii Biotech Initiates Phase 1 Clinical Trial for Dengue Vaccine
3. Herpes medication does not reduce risk of HIV transmission from individuals with HIV and genital herpes, UW-led international study finds

Story Summary: D. , Chief Scientific Officer and Vice President of Research and Development of Argos Therapeutics, added, We are excited about the Arcelis immunotherapy platform because it is so well suited to the pathology of HIV infection; it overcomes the viral variability and the immune suppressive mechanisms that allow the virus to persist chronically and, remarkably, this is achieved without activation of CD4+ T cells, which are known to serve as factories for viral replication. Data from this study show that four patients demonstrated increases in T cell proliferation specific to the four HIV antigens used in AGS-004, which met the criteria for a full response; three additional subjects demonstrated increases that represented partial responses to AGS-004 therapy. Importantly, HIV viral load was undetectable at baseline and throughout the duration of the study for all subjects. In addition to the promising immune response data observed, we have also received important data detailing a potentially favorable safety profile, as well as validation for our proprietary immunotherapy manufacturing process. About the StudyThe primary endpoint of this study was the change from baseline of the proliferative capacity of CD8+ T cells in response to the four HIV RNA-encoded antigens expressed in AGS-004. The study enrolled adults with HIV-1 infection who had plasma HIV RNA levels of fewer than 200 copies/mL, CD4+ T cell counts of greater than 350 cells/mm3, and who had been receiving their first ART regimen for at least 12 weeks prior to enrollment. AGS-004 was successfully generated and administered to 10 subjects, and 9 enrolled subjects were evaluable for the primary endpoint. The manuscript, titled, Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy, was authored by Jean-Pierre Routy, Mohamed-Rachid Boulassel, Bader Yassine-Diab, Charles Nicolette, Don Healey, Renu Jain, Claire Landry, Oleg Yegorov, Irina Tcherepanova, Tamara Monesmith, Lothar Finke, and Rafick-Pierre Sekaly. About the Arcelis TechnologyArcelis is Argos proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for HIV, other infectious diseases, and cancer. About Argos Therapeutics, Inc. Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www….Read the Full Story

Related posts:

1. Argos Therapeutics Presents Research on the Development and … – Business Wire (press release)
2. NanoBio to Announce Key Immune Response Data for Influenza at NFID Conference
3. Innate immune mechanisms can control disease progression in HIV-positive patients